MX2024011197A - Combinaciones que comprenden inhibidores de metap2 para el tratamiento de cancer. - Google Patents

Combinaciones que comprenden inhibidores de metap2 para el tratamiento de cancer.

Info

Publication number
MX2024011197A
MX2024011197A MX2024011197A MX2024011197A MX2024011197A MX 2024011197 A MX2024011197 A MX 2024011197A MX 2024011197 A MX2024011197 A MX 2024011197A MX 2024011197 A MX2024011197 A MX 2024011197A MX 2024011197 A MX2024011197 A MX 2024011197A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
combinations
metap2 inhibitors
metap2
Prior art date
Application number
MX2024011197A
Other languages
English (en)
Spanish (es)
Inventor
James Shanahan
Peter Cornelius
Bradley J Carver
Benjamin Mayes
Original Assignee
Syndevrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndevrx Inc filed Critical Syndevrx Inc
Publication of MX2024011197A publication Critical patent/MX2024011197A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2024011197A 2022-03-16 2023-03-16 Combinaciones que comprenden inhibidores de metap2 para el tratamiento de cancer. MX2024011197A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320347P 2022-03-16 2022-03-16
US202263340726P 2022-05-11 2022-05-11
PCT/US2023/064550 WO2023178255A1 (en) 2022-03-16 2023-03-16 Combinations comprising metap2 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2024011197A true MX2024011197A (es) 2024-09-18

Family

ID=85979451

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011197A MX2024011197A (es) 2022-03-16 2023-03-16 Combinaciones que comprenden inhibidores de metap2 para el tratamiento de cancer.

Country Status (9)

Country Link
US (1) US20260014194A1 (cg-RX-API-DMAC7.html)
EP (1) EP4493181A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509613A (cg-RX-API-DMAC7.html)
KR (1) KR20240164549A (cg-RX-API-DMAC7.html)
CN (1) CN119300818A (cg-RX-API-DMAC7.html)
AU (1) AU2023235307A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245962A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024011197A (cg-RX-API-DMAC7.html)
WO (1) WO2023178255A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021378944A1 (en) * 2020-11-11 2023-06-15 Syndevrx, Inc. Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3177603T3 (en) * 2014-08-04 2019-01-14 Merck Patent Gmbh PYRROLIDINE UNDERIVATIVES AS METAP-2 INHIBITORS
US11612577B2 (en) * 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof

Also Published As

Publication number Publication date
WO2023178255A9 (en) 2024-09-26
EP4493181A1 (en) 2025-01-22
AU2023235307A1 (en) 2024-10-17
KR20240164549A (ko) 2024-11-19
JP2025509613A (ja) 2025-04-11
CN119300818A (zh) 2025-01-10
CA3245962A1 (en) 2023-09-21
WO2023178255A1 (en) 2023-09-21
US20260014194A1 (en) 2026-01-15

Similar Documents

Publication Publication Date Title
MX2023013912A (es) Metodos para inhibir ras.
IL308195A (en) RAS inhibitors for cancer treatment
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
MX2023002507A (es) Inhibidores de cd73.
ZA202204941B (en) Cd73 inhibitors
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
CR20240144A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
MX2025008920A (es) Inhibidores de parp1 triciclicos y usos de estos
EP4674415A3 (en) Azaquinolines as inhibitors of cd38
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2024003713A (es) Usos de moleculas de union al antigeno multiespecificas dirigidas al ligando tipo delta 3 (dll3).
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
PH12022550130A1 (en) Enzyme inhibitors
IL316829A (en) Menin-MLL inhibitors for cancer treatment
EP3856352A4 (en) Methods of treatment of cancer comprising cdc7 inhibitors
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2023005501A (es) Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.
WO2021102359A3 (en) Taspase1 inhibitors and uses thereof